<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="35">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00048724</url>
  </required_header>
  <id_info>
    <org_study_id>P02569</org_study_id>
    <nct_id>NCT00048724</nct_id>
  </id_info>
  <brief_title>Peg-Intron for Prevention of Disease Progress in Chronic Hepatitis C Patients With Cirrhosis (Study P02569)</brief_title>
  <official_title>PEG-Intron as Maintenance Therapy vs. an Untreated Control Group in Adult Subjects With Compensated Cirrhosis (METAVIR F4), Secondary to Chronic Hepatitis C, Who Have Failed to Respond to Therapy With Any Alpha Interferon Plus Ribavirin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the safety and efficacy of PEG-Intron vs. no
      treatment for the prevention of disease progression in adult subjects with compensated
      cirrhosis secondary to chronic hepatitis C, who failed to respond to therapy with an a
      interferon plus ribavirin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Time to Observation of the First Clinical Event Experienced by a Subject</measure>
    <time_frame>Up to 60 months of treatment or observation, or when 98 subjects experience at least one clinical event</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Clinical events are liver decompensation [variceal bleeding, development of Child-Pugh Class C, hepatic encephalopathy ≥Grade 2, ascites], hepatic carcinoma, death, and/or liver transplantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Observation of the Disease Progression Experienced by a Subject</measure>
    <time_frame>Up to 60 months of treatment or observation, or when 98 subjects experience at least one clinical event</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Disease progression was observation of any clinical event defined for the primary outcome, plus any of development of Child-Pugh Class B, emergence of varices, or enlargement of pre-existing varices requiring additional therapy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">631</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <condition>Cirrhosis</condition>
  <arm_group>
    <arm_group_label>PegIntron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PegIntron (peginterferon alfa-2b) 0.5 µg/kg subcutaneously once weekly as maintenance therapy for 60 months with a 4-week post-treatment follow-up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Untreated Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>peginterferon alfa-2b (SCH 54031)</intervention_name>
    <description>0.5 µg/kg subcutaneously once weekly for 60 months</description>
    <arm_group_label>PegIntron</arm_group_label>
    <other_name>PegIntron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age at entry 18-65 years;

          -  Non-responders to previous treatment (minimum of 3 months) with an alpha interferon
             plus ribavirin;

          -  Liver biopsy demonstrating cirrhosis

        Exclusion Criteria:

          -  Any other cause for liver disease other than chronic hepatitis C;

          -  History or presence of complications of cirrhosis;

          -  Alcohol or illicit drug abuse or treatment with methadone within the past 2 years;

          -  Diseases or conditions that could interfere with participation in the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Norway</country>
    <country>Portugal</country>
    <country>Puerto Rico</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2015</verification_date>
  <lastchanged_date>March 26, 2015</lastchanged_date>
  <firstreceived_date>November 6, 2002</firstreceived_date>
  <firstreceived_results_date>April 23, 2009</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C; Cirrhosis</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
  </intervention_browse>
  <!-- Results are available for this study                                           -->
</clinical_study>
